Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Condition:   Microsatellite-stable Colorectal Cancer Interventions:   Drug: Standard of Care - mFOLFOX6;   Drug: E1 - mFOLFOX and durvalumab;   Drug: E2 - mFOLFOX6, durvalumab and oleclumab;   Drug: E3 - mFOLFOX6, durvalumab and monalizumab Sponsor:   MedImmune LLC Not yet recruiting

Source: ClinicalTrials.gov - October 30, 2019 Category: Research Source Type: clinical trials